Biotech Values

[jq1234]

Better-than-Expected Label for BMS' Ipilimumab in Melanoma

Bristol-Myers Squibb Co. is planning a quick rollout of ipilimumab following its Friday approval as the first drug to demonstrate improvement in overall survival in metastatic melanoma.

The New York-based pharma firm will get the drug, branded Yervoy, to patients "in a matter of weeks," said BMS spokeswoman Jennifer Fron Mauer. "We are all ready to go."


http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=57789